PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
1213.73%
Net income growth above 1.5x VET's 290.48%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
6.11%
D&A growth well above VET's 4.26%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
292.46%
Well above VET's 123.23% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
No Data
No Data available this quarter, please select a different quarter.
-41.66%
Both reduce yoy usage, with VET at -110.82%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-41.66%
Both reduce yoy usage, with VET at -110.82%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-72.45%
Both negative yoy, with VET at -175.58%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
13.66%
Operating cash flow growth 1.25-1.5x VET's 11.81%. Bruce Berkowitz might see better working capital management or consistent margin advantages.
-4.79%
Negative yoy CapEx while VET is 60.84%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
-100.00%
Negative yoy acquisition while VET stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
We reduce yoy sales while VET is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
-113.63%
Both yoy lines negative, with VET at -257.53%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-32.86%
We reduce yoy invests while VET stands at 50.50%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
100.00%
Debt repayment growth of 100.00% while VET is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-79.29%
Both yoy lines negative, with VET at -36.61%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
95.12%
Buyback growth of 95.12% while VET is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.